How myLoop supports a good night's sleep for the whole family
Managing diabetes at night can be particularly challenging for kids and teens. myLoop supports more stable glucose levels throughout the night and a restful night's sleep for the whole family.1,2,3
Night time diabetes management for children and teens can be complex and stressful for the whole family. The traditional diabetes management approaches - such as Multiple Daily Injections (MDI) or pump therapy - often require careful planning and proactive monitoring. This may involve waking up during the night to check glucose levels, adjusting insulin dosages, or consuming a bedtime snack to prevent lows.
Tackling nighttime challenges with myLoop
myLoop simplifies this process, offering an adaptive Automated Insulin Delivery (AID) system that personalises insulin delivery based on real-time and predicted glucose values. It helps reduce the risk of nocturnal hypo- or hyperglycaemia 1,2, supporting more stable glucose levels throughout the night. As a result, children and teens can enjoy restful night's sleep, which is crucial for their cognitive development, physical health, and emotional well-being.
Fewer nighttime disruptions for the whole family4,5
myLoop provides parents and caregivers with the convenience and peace of mind that comes from remote monitoring. Here is how Companion remote monitoring* fosters a good night of sleep:
Parents can easily check their child's glucose levels and insulin data at any time on their smartphones*, without having to wake up the child or perform a finger prick test. This allows for seamless monitoring without disturbing the child’s sleep.
In case of an emergency, such as glucose levels becoming too high or too low, the CGM not delivering readings, or a failure in insulin delivery, alarms will automatically go off. This ensures that parents are immediately alerted to any issues, enabling timely intervention to prevent any serious complications.
Personalised alarm settings: myLoop allows both users and caregivers to set personalised alarms tailored to their needs. This feature is particularly useful with adjusting alert sensitivities based on the child’s unique glucose management needs, reducing the frequency of wake-ups.
myLoop helps children, teens and their families to experience improved sleep1,2,3 and reduced nighttime monitoring burden4,5 by actively managing glucose levels during the night.
* Companion remote monitoring is compatible with Android smartphones running OS 8 and above or OS 10 and above (as of January 2025). Internet connectivity is required to share data with ”companions”.
1. Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med, 2022; 386(3):209-219. DOI: 10.1056/NEJMoa2111673.
2. Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656.
3. Musolino G. et al.: Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. Pediatr Diabetes. 2019 Sep;20(6):794-799. DOI: 10.1111/pedi.12872.
4. Rankin D. et al.: Adolescents’ and their parents’ experiences of using a closed-loop system to manage type 1 diabetes in everyday life: qualitative study. Chronic Illness. 2022;18(4):742-756. DOI: 10.1177/1742395320985924.
5. Hart R. I. et al.: Parents’ experiences of using remote monitoring technology to manage type 1 diabetes in very young children during a clinical trial: Qualitative study. Diabet Med. 2022 Jul;39(7):e14828. DOI: 10.1111/dme.14828.
For safety information on mentioned products, see mylife-diabetescare.com/safety
Disclaimer
The product images are for illustrative purposes only.
mylife and YpsoPump are registered trademarks of Ypsomed AG in several countries.
CamAPS is a registered trademark of CamDiab Ltd.
Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by mylife Diabetes Care is under license.
Other trademarks are the property of their respective owners.
myLoop: The innovation described is available in selected countries and expanding to further countries soon. Expansion is contingent upon local regulatory approval.
Insulin pumps and Automated Insulin Delivery (AID) systems can greatly improve glucose management but do not eliminate the risk of diabetic ketoacidosis (DKA). Because these systems use only rapid-acting insulin, any interruption in insulin delivery (e.g. infusion set failure, pump occlusion, empty reservoir, or device malfunction) can rapidly lead to ketosis and DKA - even if glucose readings are not very high. DKA is a serious and potentially life-threatening condition.
If you feel unwell, have persistent high glucose levels or detect positive ketones, please immediately contact your diabetes team and follow their advice. Do not rely solely on the AID system to correct high glucose or clear the ketones. Always check that insulin is being delivered and use your backup insulin method (e.g. insulin injections or insulin pens), if needed.
Medical advice can only be provided by healthcare professionals. The information contained in this material is intended for general educational purposes and should not be interpreted as medical advice or used as a substitute for consultation with a qualified healthcare professional.